$158 Million

BeiGene

Initial Public Offering

Bookrunner, February 2016

BeiGene is a Chinese clinical-stage, immuno-oncology company focused on developing molecularly targeted drugs for the treatment of cancer. The Company focuses on attacking the underlying mechanisms of cancer through not only targeted drugs, but also through the use of drug combinations. Coordinating with its belief that the treatment of cancer needs new research platforms, the Company has developed and advanced a proprietary cancer biology platform to propel its drug discovery process. The Company has developed four clinical-stage drug candidates and multiple preclinical drug candidates. The clinical stage drug candidates are molecularly targeted compounds, BGB-3111, BGB-283 and BGB-290 that inhibit validated oncology targets BTK, BRAF and PARP, respectively, and an immuno-oncology agent BGB-A317 that targets PD-1.